Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 18/20 | 0.78 |
| ▸ | CA1 | P00915 | 17/20 | 0.78 |
| ▸ | CA2 | P00918 | 17/20 | 0.78 |
| ▸ | CA12 | O43570 | 8/20 | 0.74 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.70 |
| ▸ | CA7 | P43166 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412012 | 1.00 | CA9 (0.78) | CA9CA1CA2CA12CA14 | |
| SCHEMBL15828111 | 0.94 | CA9 (0.83) | CA9CA1CA2CA12CA14 | |
| SCHEMBL2234764 | 0.92 | CA9 (0.83) | CA9CA1CA2CA12CA14 | |
| SCHEMBL13097493 | 0.91 | CA9 (0.75) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12060447 | 0.90 | CA9 (0.75) | CA9CA1CA2CA12CA14 | |
| SCHEMBL23169164 | 0.89 | CA9 (0.78) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12231697 | 0.89 | CA9 (0.75) | CA9CA1CA2CA12CA14 | |
| SCHEMBL12231957 | 0.89 | CA9 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL19954964 | 0.89 | CA9 (0.72) | CA9CA1CA2CA12CA14 | |
| SCHEMBL20622624 | 0.88 | CA9 (0.75) | CA9CA1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026214-A1 | DEVICE FOR MONITORING AN OXIDATIVE STRESS AND METHODS THEREOF | UNIV ADELAIDE (AU) | 2023-01-26 | — | — | US | claimed |
| EP-3741400-B1 | ANTI-ADHESION COMPOSITION | MOCHIDA PHARM CO LTD (JP) | 2026-03-11 | — | — | EP | disclosed |
| EP-3485921-B1 | ADHESION-PREVENTING COMPOSITION | MOCHIDA PHARM CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250144267-A1 | USE OF POLYSACCHARIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-05-08 | — | — | US | disclosed |
| US-20250032681-A1 | ANTI-ADHESION COMPOSITION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2025-01-30 | — | — | US | disclosed |
| EP-4480507-A1 | USE OF POLYSACCHARIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2024-12-25 | — | — | EP | disclosed |
| CN-118922215-A | Use of polysaccharide derivatives | 持田制药株式会社 | 2024-11-08 | — | — | CN | disclosed |
| CN-116322642-B | Polysaccharide derivative, polysaccharide derivative-drug conjugate, and method for producing same | 国立大学法人东京大学 | 2024-08-23 | — | — | CN | disclosed |
| US-11890145-B2 | Adhesion-preventing composition | THE UNIVERSITY OF TOKYO (JP) | 2024-02-06 | — | — | US | disclosed |
| US-20230416758-A1 | TRNA FRAGMENTS AND METHODS OF USE | UNIV JEFFERSON (US) | 2023-12-28 | — | — | US | disclosed |
| CN-116322642-A | Polysaccharide derivative, polysaccharide derivative-drug conjugate, and method for producing same | 国立大学法人东京大学 | 2023-06-23 | — | — | CN | disclosed |
| EP-4198060-A1 | POLYSACCHARIDE DERIVATIVE, POLYSACCHARIDE DERIVATIVE-DRUG CONJUGATE, AND METHOD FOR PRODUCING SAME | The University of Tokyo (JP) | 2023-06-21 | — | — | EP | disclosed |
| US-20230145308-A1 | ADHESION-PREVENTING COMPOSITION | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230090223-A1 | NANOPARTICLES FOR USE IN THE TREATMENT AND DIAGNOSIS OF CNS DISORDERS | UPPSALA THERAPEUTICS AB (SE) | 2023-03-23 | — | — | US | disclosed |
| US-20230026214-A1 | DEVICE FOR MONITORING AN OXIDATIVE STRESS AND METHODS THEREOF | UNIV ADELAIDE (AU) | 2023-01-26 | — | — | US | disclosed |
| EP-4110399-A1 | NANOPARTICLES FOR USE IN THE TREATMENT AND DIAGNOSIS OF CNS DISORDERS | Uppsala Theraeutics AB (SE) | 2023-01-04 | — | — | EP | disclosed |
| US-11464597-B2 | Adhesion-preventing composition | THE UNIVERSITY OF TOKYO (JP) | 2022-10-11 | — | — | US | disclosed |
| US-11382858-B2 | Active ingredient obtained from Nymphaea alba flowers | SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUE (FR) | 2022-07-12 | — | — | US | disclosed |
| CN-114674734-A | Method for evaluating antioxidant effect of cosmetic product and raw material | 无限极（中国）有限公司 | 2022-06-28 | — | — | CN | disclosed |
| WO-2022109435-A1 | TRNA FRAGMENTS AND METHODS OF USE | THOMAS JEFFERSON UNIVERSITY (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090223-A1 | NANOPARTICLES FOR USE IN THE TREATMENT AND DIAGNOSIS OF CNS DISORDERS | HPSE, PMP22, MAG | CA9 191/4885CA1 133/4885CA2 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.